Mike Hollan

The data analytics company based its new product on simple spreadsheet technology.

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

Three of the new sites will focus primarily on producing ingredients for domestic usage.

The Alpha Cognition executive discusses recent developments that positively impact the upcoming launch for ZUNVEYL.

The actor is leading a campaign focused on joint pain.

The YouScript CEO discusses new FDA guidance.

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain stable.

The CEO discusses his company’s platform that helps reformulate oral solid dose medications to liquid forms.

John Arena, interim president of global pharma services at Cencora, discusses how new technologies are shortening timelines.

Anonymous reports claim the decision came from new leadership at HHS.

John Arena, interim president of global pharma services at Cencora, discusses the importance of engaging with partners as early as possible during development in order to achieve a smooth product launch.

The campaign is based on the results of a survey that reveals the experiences of patients and caregivers in their communities.

The Blitz the Barriers initiative aims to reduce disparities among prostate cancer patients.

John Arena, interim president of global pharma services at Cencora, discusses how companies must prepare for each market and its unique regulatory requirements.

Former leaders of the CDC, FDA, and other agencies condemned the layoffs.

James Foster, CEO and co-founder of Virax Biolabs, discusses how global launches are being impacted by changing geopolitical conditions.

John Arena, interim president of global pharma services at Cencora, discusses how companies can continue to develop launch strategies while taking potential regulatory changes into consideration.

How one Big Pharma ad campaign is incorporating diversity as a driving force in improving the ways drugs are marketed directly to the patients that need them.

James Foster, CEO and co-founder of Virax Biolabs, discusses how AI and machine-learning algorithms are changing the ways that companies approach their launch strategies.

James Foster, CEO and co-founder of Virax Biolabs, discusses how companies can strategize despite hard-to-predict regulatory headwinds.

The TileDB CEO discusses how the life sciences can overcome these limitations.

James Foster, CEO and co-founder of Virax Biolabs, discusses how the industry is preparing for potential regulatory changes to vaccine policy.

Kennedy was confirmed by a mostly party-line vote in the Senate.

The energy component—and cost—associated with artificial intelligence should not be overlooked in all the excitement.

Naumovic discusses the impact that a lack of messaging can have a community.

A change in political power is altering how companies are strategizing around the IRA.

Many people are still uninformed about both the short- and long-term impacts of the virus.

The Phesi CEO discusses his company’s recent analysis of the most studied diseases in the world.

Biljana Naumovic discusses how a new study attempted to bring in patients from underserved communities.

Biljana Naumovic discusses the importance of finding ways to reach out to underserved communites.